Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s share price traded up 15.4% on Wednesday . The stock traded as high as $0.14 and last traded at $0.15, 63,069 shares changed hands during mid-day trading. A decline of 87% from the average session volume of 480,368 shares. The stock had previously closed at $0.13.
Separately, ValuEngine lowered shares of Aevi Genomic Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.
The company has a fifty day moving average price of $0.13 and a 200 day moving average price of $0.17. The stock has a market cap of $8.01 million, a PE ratio of -0.30 and a beta of 0.67.
Aevi Genomic Medicine Company Profile (NASDAQ:GNMX)
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Further Reading: What sectors are represented in the FTSE 100 index?
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.